Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia.

Nkando, Isabel; Perez-Casal, Jose; Mwirigi, Martin; Prysliak, Tracy; Townsend, Hugh; Berberov, Emil; Kuria, Joseph; Mugambi, John; Soi, Reuben; Liljander, Anne; Jores, Jörg; Gerdts, Volker; Potter, Andrew; Naessens, Jan; Wesonga, Hezron (2016). Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia. Veterinary immunology and immunopathology, 171, pp. 103-114. Elsevier 10.1016/j.vetimm.2016.02.010

[img] Text
Nkando_et_al_2016.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (879kB) | Request a copy

Mycoplasma mycoides subsp. mycoides (Mmm) is the causative agent of contagious bovine pleuropneumonia (CBPP), a devastating respiratory disease mainly affecting cattle in sub-Saharan Africa. The current vaccines are based on live-attenuated Mmm strains and present problems with temperature stability, duration of immunity and adverse reactions, thus new vaccines are needed to overcome these issues. We used a reverse vaccinology approach to identify 66 Mmm potential vaccine candidates. The selection and grouping of the antigens was based on the presence of specific antibodies in sera from CBPP-positive animals. The antigens were used to immunize male Boran cattle (Bos indicus) followed by a challenge with the Mmm strain Afadé. Two of the groups immunized with five proteins each showed protection after the Mmm challenge (Groups A and C; P<0.05) and in one group (Group C) Mmm could not be cultured from lung specimens. A third group (Group N) showed a reduced number of animals with lesions and the cultures for Mmm were also negative. While immunization with some of the antigens conferred protection, others may have increased immune-related pathology. This is the first report that Mmm recombinant proteins have been successfully used to formulate a prototype vaccine and these results pave the way for the development of a novel commercial vaccine.

Item Type:

Journal Article (Original Article)

Division/Institute:

05 Veterinary Medicine > Research Foci > Host-Pathogen Interaction
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Veterinary Bacteriology

UniBE Contributor:

Jores, Jörg

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health
600 Technology > 630 Agriculture

ISSN:

0165-2427

Publisher:

Elsevier

Language:

English

Submitter:

Achim Braun Parham

Date Deposited:

21 Jul 2017 13:08

Last Modified:

21 Jul 2017 13:08

Publisher DOI:

10.1016/j.vetimm.2016.02.010

PubMed ID:

26964722

Uncontrolled Keywords:

CBPP; Mycoplasma mycoides subsp. mycoides; Recombinant proteins; Reverse vaccinology; Subunit vaccine

BORIS DOI:

10.7892/boris.96746

URI:

https://boris.unibe.ch/id/eprint/96746

Actions (login required)

Edit item Edit item
Provide Feedback